Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02177773 · ClinicalTrials.gov registry record · Phase 1
GA-68 DOTA-TOC of Somatostatin Positive Malignancies
A Phase 1 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 1
- Development phase
- 300
- Enrollment target
NCT02177773 is a Phase 1 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 300 participants.
The verdict
NCT02177773, a Phase 1 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 300 participants
- Enrollment target
Study Summary
This phase I/II trial studies how well gallium Ga 68-DOTA-TOC positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) works in imaging patients with somatostatin receptor positive tumors. Gallium Ga 68-DOTA-TOC binds to somatostatin receptor positive tumors and can be seen using a PET scan. A PET scan uses a special camera to detect energy given off from gallium Ga 68-DOTA-TOC, to make detailed pictures of areas where material accumulates in the body. Diagnostic procedures, such as gallium Ga 68-DOTA-TOC PET/CT or PET/MRI, may help find and diagnose somatostatin receptor positive tumors and help plan the best treatment.
Interventions
- PROCEDURE Computed Tomography (CT)
- PROCEDURE Magnetic Resonance Imaging (MRI)
- PROCEDURE Positron Emission Tomography (PET)
- DRUG Gallium Ga 68-Edotreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2014-06-23 |
| Est. Completion | 2017-08-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02177773
The ClinicalTrials.gov registry entry for NCT02177773 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Computed Tomography (CT) is the first listed.
NCT02177773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02177773 about?
NCT02177773 is a clinical study titled "GA-68 DOTA-TOC of Somatostatin Positive Malignancies". This phase I/II trial studies how well gallium Ga 68-DOTA-TOC positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) works in imaging patients with somatostatin receptor positive tumors. Gallium Ga 68-DOTA-TOC binds to somatostatin receptor positive tumor...
What is the current status of trial NCT02177773?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 300 participants. The study started on 2014-06-23. Estimated completion is 2017-08-07.
What interventions are being tested in trial NCT02177773?
The interventions under investigation include: Computed Tomography (CT) (PROCEDURE), Magnetic Resonance Imaging (MRI) (PROCEDURE), Positron Emission Tomography (PET) (PROCEDURE), Gallium Ga 68-Edotreotide (DRUG).
Who is sponsoring clinical trial NCT02177773?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.